Short answer
Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). MHRA accepted pre-MAA meeting minutes for CORDStrom™ (Ebstrocel™) in RDEB.
Inmune Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- MHRA accepted pre-MAA meeting minutes for CORDStrom™ (Ebstrocel™) in RDEB
- Regulatory feedback provides a clearer pathway toward a UK Marketing Authorization Application
- Next steps and filing requirements detailed in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- MHRA written alignment de-risks CMC, non-clinical, and clinical requirements for planned 2026 UK conditional MAA
- MissionEB Phase 2 showed meaningful pain and pruritus benefits, but failed to demonstrate durable wound closure or sustained wound-burden reduction
- Regulatory positioning may support chronic or intermittent supportive therapy rather than definitive wound-healing treatment
- Phase 3 strategy shifting toward symptom-based endpoints, Bayesian analyses, and patient/parent-reported outcomes
- UK filing targeted for 2026, with EU and US submissions planned for late 2026 or early 2027 subject to alignment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inmune Bio, Inc. 8-K filings
Get the next INMB 8-K as it lands
Follow INMB for push alerts, or ask the research agent what this filing means.